Bank of America Corp DE Increases Stock Holdings in LeMaitre Vascular, Inc. $LMAT

Bank of America Corp DE boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 39.0% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 180,095 shares of the medical instruments supplier's stock after acquiring an additional 50,497 shares during the quarter. Bank of America Corp DE owned 0.79% of LeMaitre Vascular worth $19,661,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LMAT. Sound Income Strategies LLC boosted its holdings in LeMaitre Vascular by 425.6% in the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock worth $25,000 after buying an additional 183 shares during the last quarter. Catalyst Capital Advisors LLC purchased a new position in shares of LeMaitre Vascular in the first quarter valued at approximately $32,000. Geneos Wealth Management Inc. lifted its position in shares of LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after acquiring an additional 398 shares in the last quarter. EverSource Wealth Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the second quarter worth approximately $47,000. Finally, Quarry LP boosted its stake in shares of LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier's stock worth $64,000 after acquiring an additional 529 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $81.52 on Wednesday. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of 28.60, a PEG ratio of 2.38 and a beta of 0.53. The company's 50-day moving average is $94.95 and its two-hundred day moving average is $99.72. LeMaitre Vascular, Inc. has a 1-year low of $78.65 and a 1-year high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.07). The business had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.LeMaitre Vascular's revenue was up 9.6% compared to the same quarter last year. During the same period last year, the business earned $0.60 EPS. Analysts forecast that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th will be given a dividend of $0.25 per share. The ex-dividend date is Thursday, August 20th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.2%. LeMaitre Vascular's dividend payout ratio (DPR) is currently 35.09%.

Wall Street Analyst Weigh In

LMAT has been the subject of a number of research reports. Zacks Research lowered shares of LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a report on Monday, July 6th. Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. Citizens Jmp upped their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a "market outperform" rating in a research note on Wednesday, May 6th. Wells Fargo & Company dropped their price objective on shares of LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating for the company in a research note on Wednesday, August 5th. Finally, Citigroup reiterated a "market outperform" rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $110.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source